Kidney Disease in Type 2 Diabetics
-
- STATUS
- Recruiting
-
- sponsor
- AstraZeneca
Summary
Kidney Disease in Type 2 Diabetics
Description
Diabetics are at a higher risk for chronic kidney disease since high blood sugar levels caused by diabetes damage blood vessels in the kidneys. If the blood sugar level remains high over many years, this damage gradually reduces the function of the kidneys. Your kidneys filter wastes and excess fluids from your blood, which are then excreted in your urine. If you have hyperuricemia (excess of uric acid in the blood) and albuminuria (protein in the urine) this may be an indicator of chronic kidney disease.
Northern California Research is conducting a study for participants who have been diagnosed with Type 2 diabetes and hyperuricemia (excess of uric acid in the blood) and albuminuria (protein in the urine). The purpose of this study is to assess if lowering uric acid in the blood with a study medication and Febuxostat, FDA approved medication, improves kidney and/or heart function compared with a placebo.
This is a double-blind study, which means neither you nor the study doctor will know what medication group you will be placed into. You will be randomly assigned by chance (like the flip of a coin) to receive either a combination of the study medication and Febuxostat 80mg or a matching placebo. There’s a 50% chance you could receive study medication or a placebo. You will take the study medication once a day in the morning with water. The study length is 7 months (28 weeks) and includes 8 office visits. All trial-related visits, tests, and medications will be provided to you at no cost. In addition, reimbursement for trial-related time and travel may be provided.
If you suspect you may have chronic kidney disease due to elevated blood sugar levels over the past years give us a call to schedule a screening visit.
Details
| Condition | Kidney Disease, Diabetes Mellitus, Type 2, Gout (Hyperuricemia), Proteinuria |
|---|---|
| Clinical Study Identifier | TX152657 |
| Sponsor | AstraZeneca |
| Last Modified on | 25 March 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer